Ki-67 labeling index affects tumor infiltration patterns of lung squamous cell carcinoma
- Authors:
- Published online on: September 24, 2015 https://doi.org/10.3892/mmr.2015.4354
- Pages: 7303-7309
-
Copyright: © Masuda et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
Abstract
Introduction
Lung cancer is the most common type of cancer and it is the leading cause of cancer-related mortality worldwide (1). The prognosis for patients with lung cancer is generally poor, even following complete surgical resection (2), with recurrence rates of 15–30% and 5-year survival rates of 60–70% (3). There is an increasingly broad range of therapeutic options for recurrent or unresectable lung adenocarcinoma, for example, customized chemotherapy (4,5) and molecular-targeted therapies, including bevacizumab (6,7), erlotinib (4,8) and gefitinib (4). By contrast, there are few therapeutic options for recurrent lung SqCC. Therefore, accurate prognostic indicators for patients with lung SqCC are required.
Recent studies have demonstrated immunohistochemical expression patterns of cell-cycle-related molecules in lung cancer, such as p53, retinoblastoma protein, cyclin D1, p27 and Ki-67 (9–13). Ki-67 is a nuclear protein that is expressed during the G1, S, G2 and M phases of the mitotic cell cycle, although it is not expressed during the non-mitotic G0 phase (14–17). The genetic locus of Ki-67 has not yet been characterized. However, it has been assigned to chromosome 10. A number of studies have demonstrated that cell proliferative activity, as indicated by the Ki-67 labeling index (Ki-67 LI), correlates with cell growth (14–17). However, to the best of our knowledge there have been no investigations into the association between Ki-67 LI and lung cancer tumor growth patterns.
Using the general criteria for esophageal and gastric cancer studies (18–25), the tumor infiltration patterns (INF) of lung SqCC have been classified into two groups: Lung tissue specimens with and without clear boundaries between tumor tissue and healthy surrounding tissue, which are termed INFc(−) and INFc(+) respectively (24). Masuda et al (24) demonstrated that INFc(+) was significantly associated with venous invasion, the scirrhous stromal tumor type and a lower postoperative survival in patients with lung SqCC. Therefore, INFc(+) may be a useful indicator for the level of local aggressiveness and invasiveness of lung SqCC.
In the present study, the association between INF components and immunohistochemical Ki-67 LI was analyzed. The present study also investigated the clinicopathological significance of cell proliferation and tumor invasiveness at the invasive front of lung SqCCs.
Materials and methods
Lung cancer specimens
Cancer tissue specimens were obtained from surgically resected lung SqCC tissue following obtaining informed consent from 89 patients (85 males and four females; age range, 43–85 years; mean age, 67.2 ± 0.9 years). The study was approved by the ethics committee of the Institutional Review Board of Tokai University Hospital (Isehara, Japan). All patients had undergone radical surgery (lobectomy and mediastinal lymphadenectomy) at Tokai University Hospital between January 2001 and December 2006. Tumor stages were defined according to the TNM classification of the International Union Against Cancer (UICC; 5), and the histological types were defined according to the World Health Organization classification (26). The median postoperative follow-up duration was 1,572 days (range 41–3,837 days).
Histological examination
Lung tissue specimens were immediately fixed with 10% buffered formalin for 24–48 h and embedded in paraffin (Wako Pure Chemical. Industries Ltd., Osaka, Japan). Tissue samples were cut at 5–10 mm intervals. Tumor invasion and lymphatic invasion were examined in 4-µm sections, that were stained with hematoxylin and eosin. The extent of lymphatic invasion in the tissue specimens was classified as follows: ly0, no lymphatic invasion; ly1+, mild lymphatic invasion; ly2+, moderate lymphatic invasion; and ly3+, severe lymphatic invasion. Vascular and pleural invasion was evaluated using Elastica van Gieson staining for detection of elastic fibres. The degree of venous invasion in the tissue specimens was classified as follows: v0, no venous invasion; v1+, minimal venous invasion (one or two foci of venous invasion in one histological section); v2+, moderate venous invasion (three or four foci); or v3+, severe venous invasion (five or more foci).
INF at the invasive front of the SqCC was classified into three groups according to the general criteria for gastric cancer studies (18–20,24): INFa, cancer nests exhibit expanding growth and a distinct boundary with the surrounding tissue; INFb, the manner of growth and invasive pattern is intermediate between those of INFa and INFc; and INFc, cancer nests exhibit infiltrative growth without a clear boundary between the tumor tissue and surrounding healthy tissue. However, a number of samples exhibited intermediate characteristics, for example, INFa>b (5,20,27). Therefore, SqCC tissue specimens were further classified into seven categories: INFa, INFa>b, INFa<b, INFb, INFb>c, INFb<c and INFc. These seven categories were allocated into two broader groups: Those cases with an INFc component [INFc(+); comprising INFb>c, INFb<c and INFc], and those without an INFc component [INFc (−); comprising INFa, INFa>b, INFa<b and INFb].
The stromal types, that is, cancer cells/stroma (c/s) ratio in the cancerous lesion were also classified into three groups: Medullary type, the stroma is limited (high c/s ratios); intermediate type, the quantity of stroma is intermediate between those of the scirrhous and medullary types (intermediate c/s ratios); and scirrhous type, the stroma is abundant (low c/s ratios) t (19).
Immunohistochemical analysis
Deparaffinized and dehydrated 4-µm paraffin sections were immersed in 0.3% hydrogen peroxide (H2O2) in methanol (Wako Pure Chemical. Industries Ltd.) for 30 min in order to abolish endogenous peroxidase activity. Subsequently, the sections were mounted on aminoacyl silane-coated glass slides and used for immunohistochemical analysis of Ki-67 expression (Ki-67; rabbit monoclonal; cat. no. 418071; Nichirei Bioscience, Tokyo, Japan). In order to facilitate Ki-67 antigen retrieval, the sections were penetrated by autoclave heating (ES-215, High-pressure steam sterilizer; Tomy Seiko Co., LTD, Tokyo, Japan) at 121°C for 4 min. Non-specific binding was abolished using diluted normal sheep serum (Cosmo Bio Co., Ltd, Tokyo, Japan). Subsequently, a primary monoclonal antibody, diluted 1:100 in 1% bovine serum albumin (Wako Pure Chemical. Industries Ltd.) and phosphate-buffered saline (PBS), was added and incubated overnight at 4°C in a moist chamber. Following a wash phase using PBS, a secondary anti-rabbit IgG peroxidase-linked antibody (cat. no. NA934) at 1:100 dilution (Amersham International plc., Little Chalfont, UK) was applied for 60 min at room temperature. The sections were then treated with streptavidin-conjugated horseradish peroxidase for 30 min at room temperature (Funakoshi Co., Ltd., Tokyo, Japan). The reaction products were visualized using diaminobenzidine tetrahydrochloride (Muto Pure Chemicals Co., Ltd., Tokyo, Japan) for 4 min in Tris buffer.
Evaluation of Ki-67 LI
Cells were observed using a 40x objective microscope (BX50; Olympus, Tokyo, Japan). In each section, ≤1,000 cells were randomly selected and the positive cells were counted. The cut-off point for positivity was considered when ≥30% positive cells were observed. Samples were classified into two groups: high-grade cell proliferation (Ki-67 LI ≥30%) and low-grade cell proliferation (Ki-67 LI <30%).
Statistical analysis
Univariate analyses (chi-square tests) were primarily used for identifying all variables that exhibited statistically significant differences. P<0.05 was considered to indicate a statistically significant difference. Cox proportional hazards regression analysis was conducted in order to determine the effect of each predictor variable, using univariate analyses. Univariate and multivariate analyses were conducted in order to investigate the association between Ki-67 LI and SqCC tumor invasion. Propensity scores were calculated in the multivariate analysis, in order to measure the effect of the following covariates on INFc(+): Age at surgery, gender, tumor size, lymph node metastasis, lymphatic invasion, histological differentiation and stromal type. Hazard ratios (HR) and 95% confidence intervals (CI) were used to assess the independent contributions of significant factors. In all cases P<0.05 was considered to indicate a statistically significant difference.
The patient survival time was measured from the date of surgery to mortality, related to any cause (without discrimination between mortalities resulting from lung carcinoma and other causes). Survival curves were created using the Kaplan-Meier method and compared using the log-rank test. All analyses were performed using the SPSS II statistical software package (version 19.0; SPSS, Inc., Chicago, IL, USA).
Results
Lung SqCC cell proliferation
High-grade cell proliferation (≥30% Ki-67 LI) and low-grade cell proliferation (<30% Ki-67 LI) was observed in 16.9% (15/89) and 83.1% (74/89) of SqCC lung cancer specimens, respectively (Fig. 1). Associations between Ki-67 LI and clinicopathological features are summarized in Table I. INFc(+) was most common in SqCC lung cancer specimens with high-grade cell proliferation (≥30% Ki-67 LI) compared with those with low-grade cell proliferation (<30% Ki-67 LI; P=0.03). However, no significant difference was detected in prognosis between the high and low Ki-67 LI groups.
Tumor growth patterns of lung SqCC
Lung tissue specimens were initially categorized into three INF groups (Fig. 2). They were further classified into seven groups based on the INF of each specimen: INFa (10, 11.2%), INFa>b (8, 9.0%), INFa<b (0, 0%), INFb (37, 41.6%), INFb>c (27, 30.3%), INFb<c (3, 3.4%) and INFc (4, 4.5%). The patients with INFc(+) (INFb>c, b<c, c) had a poor outcome, compared with the patients with INFc(−) (INFa,a>b, a<b, b) (Table II). The associations between INFc(+) and clinicopathological features of patients with lung SqCC according to a univariate analysis, are summarized in Table III. INFc(+) was significantly associated with venous invasion (P=0.032; HR, 2.615; 95% CI, 1.085–6.305), stromal type (P<0.001; HR, 6.462; 95% CI, 2.483–16.817) and Ki-67 LI (P=0.044; HR, 4.952; 95% CI, 1.043–23.523) of lung SqCC. INFc(+) cases exhibited a significantly poorer prognosis compared with INFc (−) cases (P=0.012; Fig. 3).
Multivariate analyses for prediction of INFc
Propensity scores were calculated by measuring the effect of the following covariates on INFc(+): Age at surgery, gender, tumor size, lymph node metastasis, lymphatic invasion, histological differentiation and stromal type. Multivariate logistic regression analysis demonstrated that INFc(+) was significantly associated with Ki-67 LI (odds ratio, 12.5; 95% CI, 1.5–102.8; P=0.018) and stromal type (odds ratio, 8.4; 95%, CI, 2.9–24.1; P<0.001) following adjustment for the propensity score (Table IV).
Discussion
As a result of the advances in imaging, diagnostic techniques and operative procedures, the number of patients with lung SqCC undergoing surgical resection has increased for the last three decades. In the present study, 89 surgically resected specimens of lung tissue from patients with lung SqCC were analyzed in order to investigate tumor aggressiveness. INF and local tumor proliferation in lung SqCC were analyzed by measuring cell proliferation, using Ki-67 expression as a proxy. INFc(+) was most common in the lung tissue samples from cases with high-grade cell proliferation (Ki-67 LI ≥30%) compared with those from cases with low grade cell proliferation (Ki-67 LI<30%). To the best of our knowledge, this is the first report of an association between INF and lung SqCC cell proliferation.
A previous study demonstrated a correlation between the survival rate of patients with lung SqCC, and tumor budding and histological aggressiveness (24). In the present study, a significantly greater number of INFc(+) lung SqCC specimens exhibited high-grade than low-grade cell proliferation. These results suggest that high-grade cell proliferation may affect the infiltrative growth of cancer nests. Furthermore, INFc(+) was significantly associated with the scirrhous stromal type and positive venous invasion (Table III).
A number of meta-analyses have addressed the prognostic value of Ki-67 in lung cancer. However its clinicopathological role remains to be elucidated (28–34). Ciancio et al (9) demonstrated that Ki-67 immunostaining of lung tissue specimens obtained from patients with non-small cell lung cancer (NSCLC) using fiber-optic bronchoscopy, may be useful for making prognostic predictions for patients with lung SqCC. Ciancio et al (9) demonstrated that 42.1% of the lung cancer cases exhibited high-grade cell proliferation (Ki-67 LI > 25%). By contrast, the present study demonstrated that 83.1% of SqCC lung cancer specimens exhibited high-grade cell proliferation (Ki-67 LI > 30%). The present study analyzed lung cancer tissues taken from surgical resection, and therefore examined entire tumor, whereas the investigation of Ciancio et al (9) used lung cancer specimens obtained by biopsy. It is hypothesized that the different procedure used for obtaining the specimens (biopsy vs. surgical resection) between Ciancio et al (9) and the present study, may explain the contrasting results in the percentage of lung cancer specimens exhibiting high-grade cell proliferation. Furthermore, Ciancio et al (9) examined Ki-67 overexpression in NSCLC cells and the clinical outcomes for patients with NSCLC, which included SqCC, adenocarcinoma and other histological types. By contrast, the present study focussed on SqCC lung tissue. In terms of patient survival, the results of the present study are in accordance with the conclusions of Ciancio et al (9). The present study demonstrated that INFc(+) may be a prognostic factor in SqCC. However, further investigations are required in order to examine the molecular and histological associations between tumor invasiveness and high-grade cell proliferation in lung SqCC.
In conclusion, high-grade cell proliferation, as measured by Ki-67 LI, significantly correlated with an INF that indicated a more aggressive lung SqCC. Ki-67 LI may therefore be used as an indicator of INFc(+) and is a potential prognostic factor for lung SqCC.
Acknowledgments
The authors would like to thank Professor Hiroyuki Kobayashi (Department of Clinical Pharmacology, Tokai University School of Medicine, Isehara, Kanagawa) for help with the statistical analysis.
References
|
Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar | |
|
Beadsmoore CJ and Screaton NJ: Classification, staging and prognosis of lung cancer. Eur J Radiol. 45:8–17. 2003. View Article : Google Scholar | |
|
Goldstraw P, Crowley J, Chansky K, et al: The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol. 2:706–714. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Hong J, Kyung SY, Lee SP, et al: Pemetrexed versus gefitinib versus erlotinib in previously treated patients with non-small cell lung cancer. Korean J Intern Med. 25:294–300. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Rossi A, Ricciardi S, Maione P, de Marinis F and Gridelli C: Pemetrexed in the treatment of advanced non-squamous lung cancer. Lung Cancer. 66:141–149. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Sandler A, Gray R, Perry MC, et al: Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 355:2542–2550. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Reck M, von Pawel J, Zatloukal P, et al: Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol. 27:1227–1234. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Rosell R, Perez-Roca L, Sanchez JJ, et al: Customized treatment in non-small-cell lung cancer based on EGFR mutations and BRCA1 mRNA expression. PLoS One. 4:e51332009. View Article : Google Scholar : PubMed/NCBI | |
|
Ciancio N, Galasso MG, Campisi R, Bivona L, Migliore M and Di Maria GU: Prognostic value of p53 and Ki67 expression in fiberoptic bronchial biopsies of patients with non small cell lung cancer. Multidiscip Respir Med. 7:292012. View Article : Google Scholar : PubMed/NCBI | |
|
Kosacka M, Piesiak P, Kowal A, Gołecki M and Jankowska R: Galectin-3 and cyclin D1 expression in non-small cell lung cancer. J Exp Clin Cancer Res. 30:1012011. View Article : Google Scholar : PubMed/NCBI | |
|
Sterlacci W, Fiegl M, Hilbe W, et al: Deregulation of p27 and cyclin D1/D3 control over mitosis is associated with unfavorable prognosis in non-small cell lung cancer, as determined in 405 operated patients. J Thorac Oncol. 5:1325–1336. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Lei B, Liu S, Qi W, et al: PBK/TOPK expression in non-small-cell lung cancer: its correlation and prognostic significance with Ki67 and p53 expression. Histopathology. 63:696–703. 2013.PubMed/NCBI | |
|
Motadi LR, Bhoola KD and Dlamini Z: Expression and function of retinoblastoma binding protein 6 (RBBP6) in human lung cancer. Immunobiology. 216:1065–1073. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Cattoretti G, Becker MH, Key G, et al: Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. J Pathol. 168:357–363. 1992. View Article : Google Scholar : PubMed/NCBI | |
|
Gerdes J, Li L, Schlueter C, et al: Immunobiochemical and molecular biologic characterization of the cell proliferation-associated nuclear antigen that is defined by monoclonal antibody Ki-67. Am J Pathol. 138:867–873. 1991.PubMed/NCBI | |
|
Hui AM, Shi YZ, Li X, et al: Proliferative marker Ki-67 in gallbladder carcinomas: high expression level predicts early recurrence after surgical resection. Cancer Lett. 176:191–198. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Xuan YH, Choi YL, Shin YK, et al: An immunohistochemical study of the expression of cell-cycle-regulated proteins p53, cyclin D1, RB, p27, Ki67 and MSH2 in gallbladder carcinoma and its precursor lesions. Histol Histopathol. 20:59–66. 2005. | |
|
Haraguchi M, Yamamoto M, Saito A, et al: Prognostic value of depth and pattern of stomach wall invasion in patients with an advanced gastric carcinoma. Semin Surg Oncol. 10:125–129. 1994. View Article : Google Scholar : PubMed/NCBI | |
|
Japanese Classification of Gastric Carcinoma - 2nd English Edition. Gastric Cancer. 1:10–24. 1998. View Article : Google Scholar | |
|
Maehara Y, Oshiro T, Adachi Y, Ohno S, Akazawa K and Sugimachi K: Growth pattern and prognosis of gastric cancer invading the subserosa. J Surg Oncol. 55:203–208. 1994. View Article : Google Scholar : PubMed/NCBI | |
|
Okada K, Kijima H, Imaizumi T, et al: Wall-invasion pattern correlates with survival of patients with gallbladder adenocarcinoma. Anticancer Res. 29:685–691. 2009.PubMed/NCBI | |
|
Song KY, Hur H, Jung CK, et al: Impact of tumor infiltration pattern into the surrounding tissue on prognosis of the subserosal gastric cancer (pT2b). Eur J Surg Oncol. 36:563–567. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Kong KY, Park JY, Kim DY, et al: Prognostic significance of stromal microinvasion in the intestinal type of ovarian mucinous adenocarcinoma. Ann Surg Oncol. 18:3462–3468. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Masuda R, Kijima H, Imamura N, et al: Tumor budding is a significant indicator of a poor prognosis in lung squamous cell carcinoma patients. Mol Med Rep. 6:937–943. 2012.PubMed/NCBI | |
|
Sobin LH, Gospodarowicz MK and Wittekind C: TNM Classification of Malignant Tumors. 7th edition. Wiley; Hoboken, New Jersey, NJ, USA: 2010 | |
|
Travis WD, Brambilla E, Muller-Hermedin HK and Harris CC: Pathology and Genetics Tumours of the Lung, Pleura, Thymus and Heart. IARC Press; Lyon, France: 2004 | |
|
Kawano K and Yanagisawa S: Predictive value of laminin-5 and membrane type 1-matrix metalloproteinase expression for cervical lymph node metastasis in T1 and T2 squamous cell carcinomas of the tongue and floor of the mouth. Head Neck. 28:525–533. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Soomro IN and Whimster WF: Growth fraction in lung tumours determined by Ki67 immunostaining and comparison with AgNOR scores. J Pathol. 162:217–222. 1990. View Article : Google Scholar : PubMed/NCBI | |
|
Scagliotti GV, Micela M, Gubetta L, et al: Prognostic significance of Ki67 labelling in resected non small cell lung cancer. Eur J Cancer. 29A:363–365. 1993. View Article : Google Scholar : PubMed/NCBI | |
|
Hommura F, Dosaka-Akita H, Mishina T, et al: Prognostic significance of p27KIP1 protein and ki-67 growth fraction in non-small cell lung cancers. Clin Cancer Res. 6:4073–4081. 2000.PubMed/NCBI | |
|
Nguyen VN, Mirejovský P, Mirejovský T, Melinova L and Mandys V: Expression of cyclin D1, Ki-67 and PCNA in non-small cell lung cancer: prognostic significance and comparison with p53 and bcl-2. Acta Histochem. 102:323–338. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Maddau C, Confortini M, Bisanzi S, et al: Prognostic significance of p53 and Ki-67 antigen expression in surgically treated non-small cell lung cancer: immunocytochemical detection with imprint cytology. Am J Clin Pathol. 125:425–431. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Ishida H, Irie K, Itoh T, Furukawa T and Tokunaga O: The prognostic significance of p53 and bcl-2 expression in lung adenocarcinoma and its correlation with Ki-67 growth fraction. Cancer. 80:1034–1045. 1997. View Article : Google Scholar : PubMed/NCBI | |
|
Martin B, Paesmans M, Mascaux C, et al: Ki-67 expression and patients survival in lung cancer: systematic review of the literature with meta-analysis. Br J Cancer. 91:2018–2025. 2004. View Article : Google Scholar : PubMed/NCBI |
